AT-587 Phase 1 Initiation: Potent Preclinical Signal, But Human Proof-of-Concept Remains the Critical Unresolved Question

Atea Pharmaceuticals Initiates Phase 1 Trial for AT-587 in Hepatitis E

Atea Pharmaceuticals announced the initiation of a first-in-human Phase 1 clinical trial for AT-587, an oral antiviral nucleotide analog, to treat hepatitis E virus (HEV) infection. HEV is a serious liver disease with no approved therapies, particularly affecting immunocompromised individuals. The randomized, double-blind, placebo-controlled, sequential dose-escalation study will evaluate the safety, tolerability, and pharmacokinetics of AT-587 in healthy volunteers, with both single and multiple ascending dose components. Preclinical data presented at EASL Congress 2026 showed AT-587's potent antiviral activity against HEV, being 30- to 150-fold more potent than sofosbuvir and ribavirin in vitro, and effective in an in vivo gerbil model.

• The Phase 1 trial for AT-587 is a randomized, double-blind, placebo-controlled, sequential dose-escalation study designed to evaluate the safety, tolerability, and pharmacokinetics (PK) of the drug in healthy volunteers. The study includes both single ascending dose (SAD) and multiple ascending dose (MAD) components, as well as an embedded food-effect assessment, allowing for flexible dose adjustments based on emerging clinical data.
• Encouraging preclinical data for AT-587 was presented at EASL Congress 2026, demonstrating potent antiviral activity against HEV. In vitro studies showed AT-587 to be 30- to 150-fold more potent than off-label treatments like sofosbuvir and ribavirin. Furthermore, in an HEV genotype 3 infected gerbil model, treated groups exhibited significantly lower HEV RNA levels, confirming its in vivo efficacy.
• Hepatitis E Virus (HEV) poses a significant global health challenge, especially for immunocompromised patients who are at high risk for chronic infection, cirrhosis, and liver failure. With no approved antiviral therapies and limited efficacy and tolerability of current off-label options such as ribavirin, AT-587 represents a potential first-in-class treatment to address this substantial unmet medical need, particularly for transplant recipients and other vulnerable populations.

Addressing the Urgent Unmet Need in Hepatitis E Virus

Despite growing recognition of hepatitis E virus (HEV) as a significant global health burden, critical gaps persist in surveillance, prevention, and access to care across a range of high-risk populations. Recent literature from 2024–2026 highlights both the breadth of vulnerable groups affected and the systemic failures that leave them underserved.

• Pregnant women and newborns remain among the most clinically vulnerable populations, at elevated risk of severe hepatic complications and mortality from HEV infection — underscoring the urgency for comprehensive monitoring and targeted prevention strategies.

• Immunocompromised patients — including solid organ transplant recipients (SOTRs), hemodialysis patients, and individuals with HIV — face disproportionate disease burden. Among SOTRs with active or recent HEV infection, 30% developed a chronic course, with some requiring ribavirin therapy for virologic resolution. In hemodialysis patients in Ankara, Turkey, HEV-IgG seroprevalence reached 26.25%, rising to 47.4% in those over 65 years of age.

• Chronic hepatitis B (CHB) patients superinfected with HEV incur significantly longer disease courses, greater economic burden, and higher health loss compared to HEV monoinfection (all p < 0.05). A screening-based hepatitis E vaccination strategy in this population has been identified as the most cost-effective intervention, with an ICER of 29,147.32 yuan/QALY — well below China's per-capita GDP threshold.

• Low-resource, rural, and displaced populations face compounding vulnerabilities: 78% of HEV cases in Uttar Pradesh, India reported consuming unfiltered water; residents using alternative sewage systems in metropolitan Northeast Brazil showed higher odds of HEV positivity (OR = 1.58; 95% CI: 1.08–2.31; p = 0.021); and ethnic minority students in Northern Vietnam demonstrated a 25% anti-HEV IgG seroprevalence, with consumption of raw or undercooked pork liver (p = 0.018) as a significant risk factor.

• Surveillance and diagnostic gaps represent a foundational unmet need: 47.8% of published studies failed to report HEV genotype data, outbreaks are frequently excluded from burden-of-disease estimates, and seroprevalence data in regions such as Saudi Arabia and Nepal remain outdated or geographically limited — making it difficult for stakeholders to prioritize and allocate resources effectively.

• Intervention timing and integration are critical yet insufficiently addressed: modelling data indicate that combined early deployment of WASH (water, sanitation, and hygiene) programmes and HEV vaccination can reduce overall and severe infections by approximately 94%, whereas delayed deployment reduces this efficacy to 67%. WASH alone was more than twice as effective as vaccination alone in reducing total infections, though vaccination produced a disproportionately larger reduction in severe disease (46% vs. 26–31%).

• Equitable access to care remains a persistent structural gap, with treatment access reported to be 35% lower in rural areas in Saudi Arabia, and healthcare access further constrained for migrant populations — highlighting the need for targeted strategies aligned with WHO 2030 elimination goals.

AT-587's Potential to Redefine HEV Treatment Landscape

The current standard of care for HEV infection relies primarily on off-label use of ribavirin and pegylated interferon-alpha (PEG-IFN), both of which carry meaningful efficacy limitations and tolerability concerns. A 2021 systematic meta-analysis of 395 patients demonstrated a pooled sustained virologic response (SVR) rate of 78% (95% CI 72%–84%) for ribavirin in chronic hepatitis E, with rapid virologic response achieved in 25% of patients; however, relapse occurred in 18%, and anaemia necessitated dose reduction, erythropoietin use, or transfusion in 37% of cases. More recent pharmacokinetic modelling (2025) in 107 chronically HEV-infected solid organ transplant (SOT) recipients further refined optimal ribavirin dosing to 600 mg/day, 400 mg/day, or 200 mg/day for 180 days, stratified by eGFR, demonstrating that viral load decline is independent of ribavirin concentration due to a low IC50, whereas haematological toxicity scales directly with dose and exposure. PEG-IFN has shown an 85% SVR rate across 13 treated patients but carries a 15% risk of acute transplant rejection, substantially restricting its use in immunocompromised populations. Across multiple time periods, ribavirin and PEG-IFN have been characterised as insufficient and unsafe in certain patient subgroups due to embryoteratogenic effects, leukopenia, and thrombocytopenia, underscoring a clear unmet need for HEV-specific antiviral agents.

Several investigational antiviral agents have demonstrated preclinical and early-stage promise in comparison to these standard-of-care benchmarks. Apilimod, a PIKfyve inhibitor, emerged as the most potent antiviral among five HEV-inhibitory compounds identified in a 2026 screening study, which also identified raloxifene, verapamil, chloroquine, and tamoxifen as active agents. Apilimod acts specifically during viral entry rather than replication, disrupting lysosomal organisation, impairing HEV trafficking to late endosomal/lysosomal compartments, and reducing lysosomal cathepsin activity. Critically, it significantly reduced HEV infectivity in primary human hepatocytes and decreased viral RNA levels in faecal and tissue samples in a rat HEV infection model in vivo, with a pre-existing human clinical safety profile supporting its translational potential. Separately, type III interferons (interferon λ1–3) were identified in 2020 as potentially effective against HEV using replicon and cell-culture systems with a genotype 3 strain, offering a mechanistic rationale for further investigation given their more hepatocyte-restricted receptor expression compared to PEG-IFN.

On the prophylactic front, the recombinant HEV 239 vaccine (Hecolin®) has established a robust efficacy and safety dataset that far exceeds any currently available therapeutic intervention. A three-dose regimen demonstrated 95.5% vaccine efficacy (95% CI 85.6–98.6) in a 2007 phase 2 trial in Nepal, with long-term follow-up data from a 2015 study of 112,604 adults confirming 86.8% efficacy (95% CI 71–94) sustained over 4.5 years; 87% of vaccinated participants maintained anti-HEV antibodies throughout that period. A 2023 two-dose regimen study confirmed 100% seroconversion with detectable T-cell responses at one month, and antibody persistence in all but one participant at two years. A 2025 evaluation of a thiomersal-free formulation showed non-inferior immunogenicity versus the licensed vaccine, with a seroconversion rate difference of 0.00% (95% CI −1.38 to 1.34) and comparable safety profiles. Collectively, while prophylactic vaccine data are the most mature and compelling, the investigational antiviral pipeline — particularly apilimod — represents a meaningful step toward filling the therapeutic gap left by ribavirin and PEG-IFN.

Pioneering a Path for Dedicated HEV Treatment

Hepatitis E virus (HEV) infection represents a critical global health challenge, especially for immunocompromised patients who face a heightened risk of chronic infection, leading to severe liver disease and even mortality. The current therapeutic landscape is notably barren, relying on off-label use of drugs like ribavirin, which can be suboptimal, or sofosbuvir, which has shown only modest antiviral activity in some studies. This significant unmet need underscores the importance of novel therapeutic approaches.

The initiation of a Phase 1 clinical trial for AT-587, an oral nucleotide analog, offers a beacon of hope. Nucleotide analogs have a well-established track record of success in treating other viral hepatitis infections, such as chronic hepatitis B with adefovir and hepatitis C with sofosbuvir, by directly inhibiting viral replication machinery. This class of drugs is often characterized by potent antiviral activity, a high barrier to resistance, and favorable safety profiles.

Preclinical data for AT-587 are particularly encouraging, demonstrating significantly higher potency against HEV compared to existing off-label options. If these promising results translate into clinical efficacy and safety in humans, AT-587 could redefine the treatment paradigm for HEV. However, the journey from preclinical promise to an approved therapy is fraught with challenges:

• Translational Risk: The robust preclinical potency must be replicated in human trials, where drug pharmacokinetics and host-virus interactions can differ significantly.

• Resistance Development: While nucleotide analogs generally have a high barrier to resistance, the potential for viral mutations to emerge over extended treatment periods, as seen with some HCV therapies, warrants careful monitoring.

• Competitive Landscape: Other investigational therapies, including different nucleotide analogs like bemnifosbuvir, are also advancing, suggesting a potentially competitive future market for HEV treatments.

Despite these considerations, the advancement of AT-587 into clinical development represents a pivotal moment. It signifies a dedicated effort to provide a much-needed, effective, and well-tolerated treatment for a vulnerable patient population, potentially establishing a new standard of care and offering a significant improvement over current suboptimal options.